NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) Chairman Jonathan C. Javitt acquired 40,000 shares of the stock in a transaction dated Tuesday, December 17th. The stock was acquired at an average cost of $1.17 per share, for a total transaction of $46,800.00. Following the purchase, the chairman now directly owns 84,634 shares in the company, valued at approximately $99,021.78. The trade was a 89.62 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
NRx Pharmaceuticals Trading Down 5.8 %
Shares of NASDAQ:NRXP opened at $1.55 on Thursday. NRx Pharmaceuticals, Inc. has a 1 year low of $1.10 and a 1 year high of $7.33. The stock has a market capitalization of $18.69 million, a PE ratio of -0.72 and a beta of 1.25. The firm has a fifty day moving average price of $1.28 and a 200 day moving average price of $1.88.
Institutional Investors Weigh In On NRx Pharmaceuticals
A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Anson Funds Management LP purchased a new position in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 142,525 shares of the company's stock, valued at approximately $241,000. Anson Funds Management LP owned about 1.33% of NRx Pharmaceuticals as of its most recent SEC filing. 4.27% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Last time you’ll see this priced at $1.00
From StocksToTrade | Ad
When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!
Click here to review Tim’s special offer before it’s too late.
A number of equities analysts recently issued reports on NRXP shares. EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a "strong-buy" rating in a report on Monday, October 21st. Ascendiant Capital Markets raised their target price on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a "buy" rating in a report on Monday, December 2nd. Finally, HC Wainwright restated a "buy" rating and set a $19.00 price target on shares of NRx Pharmaceuticals in a report on Monday, November 25th.
View Our Latest Report on NRXP
About NRx Pharmaceuticals
(
Get Free Report)
NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
